Adagrasib

Major

Adagrasib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine exposure and reduced active metabolite (morphine) exposure Details Adagrasib Amitriptyline Elavil Explained An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Sertraline Explained An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Adagrasib Colchicine Colcrys Explained Increased exposure to P-gp substrates and an increased risk of P-gp substrates-related adverse effects Details Adagrasib Simvastatin Flolipid Explained Increased CYP3A4 substrate exposure Details Adagrasib Abemaciclib Verzenio Explained Increased CYP3A4 substrate exposure Details Adagrasib Acalabrutinib Calquence Increased CYP3A4 substrate exposure Details Adagrasib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Adagrasib Amisulpride Injection Barhemsys An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Apixaban Eliquis Explained Increased apixaban exposure and an increased risk of bleeding Details Adagrasib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Adagrasib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Adagrasib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Atogepant Qulipta Increased atogepant exposure Details Adagrasib Avapritinib Ayvakit Increased CYP3A4 substrate exposure Details Adagrasib Azithromycin AzaSite An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Adagrasib Alfuzosin UroXatral An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Adagrasib Anagrelide Agrylin An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Avanafil Stendra Increased CYP3A4 substrate exposure Details Adagrasib Beclomethasone Nasal Spray Beconase Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Adagrasib Beclomethasone Oral Inhalation Beclovent® Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Adagrasib Bedaquiline Sirturo An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Bosutinib Bosulif Increased CYP3A4 substrate exposure Details Adagrasib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Adagrasib Budesonide Entocort Increased CYP3A4 substrate exposure Details Adagrasib Budesonide Nasal Spray Rhinocort Increased CYP3A4 substrate exposure Details Adagrasib Budesonide Oral Inhalation Pulmicort Increased CYP3A4 substrate exposure Details Adagrasib Cabozantinib Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Adagrasib Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Adagrasib Chloroquine Aralen® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Cobimetinib Cotellic Increased CYP3A4 substrate exposure Details Adagrasib Cyclosporine Injection Atopica Increased exposure to CYP3A/P-gp substrates Details Adagrasib Cyclosporine Ophthalmic Cequa Increased exposure to CYP3A/P-gp substrates Details Adagrasib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details